NAGE Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 0.11%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Astrana Health, Inc.'s return on equity of 1.85%.

Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 209.2%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 96.04%. Given that Niagen Bioscience, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Astrana Health, Inc..

Niagen Bioscience, Inc. has a beta of 2.345, which suggesting that the stock is 134.544% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.555%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.00x while Astrana Health, Inc.'s PE ratio is 97.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 3.46x versus 0.31x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 9.32%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Corcept Therapeutics, Inc.'s return on equity of 16%.

Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 209.2%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $94.20 which suggests that it could grow by 128.03%. Given that Niagen Bioscience, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Corcept Therapeutics, Inc..

Niagen Bioscience, Inc. has a beta of 2.345, which suggesting that the stock is 134.544% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Niagen Bioscience, Inc.'s net income of $4.6M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.00x while Corcept Therapeutics, Inc.'s PE ratio is 47.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 3.46x versus 6.66x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Harrow, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 1.42%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Harrow, Inc.'s return on equity of -8.95%.

Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 209.2%. On the other hand Harrow, Inc. has an analysts' consensus of $70.63 which suggests that it could grow by 48.81%. Given that Niagen Bioscience, Inc. has higher upside potential than Harrow, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Harrow, Inc..

Niagen Bioscience, Inc. has a beta of 2.345, which suggesting that the stock is 134.544% more volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.073, suggesting its less volatile than the S&P 500 by 92.734%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Harrow, Inc. quarterly revenues of $71.6M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Harrow, Inc.'s net income of $1M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.00x while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 3.46x versus 7.09x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 17.41%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 209.2%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $338.57 which suggests that it could grow by 36.01%. Given that Niagen Bioscience, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than West Pharmaceutical Services, Inc..

Niagen Bioscience, Inc. has a beta of 2.345, which suggesting that the stock is 134.544% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.063%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.35% to investors and pays a quarterly dividend of $0.22 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Niagen Bioscience, Inc.'s net income of $4.6M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.00x while West Pharmaceutical Services, Inc.'s PE ratio is 36.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 3.46x versus 6.01x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.